Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients
Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between February 15 and March 15, 2023. The primary outcome was time to sustained clinical recovery through Day 28 and secondary outcomes included the percentage of participants who died from any cause by Day 28, the average hospitilization time and expenses, the changes in liver and kidney function and adverse events. The Kaplan–Meier method and Cox regression model was used for statistical analysis. Results There was no significant difference between azvudine and paxlovid in terms of time to sustained clinical recovery (p = 0.429) and death rates (p = 0.687). As for hospitalization time and fee, no significant differences were observed between azvudine group and paxlovid group (Hospitalization time: p = 0.633; Hospitalization fee: p = 0.820). In addition, there were no significant differences in the effects of the two drugs on liver and kidney function (p > 0.05). Conclusion Among adults who were hospitalised with SARS-CoV-2 infection, azvudine was noninferior to paxlovid in terms of time to sustained clinical recovery, death rates, hospitalization time and cost, with few safety concerns. Trial registration ChiCTR2300071309; Registered 11 May 2023. Level of evidence Level III; Retrospective cohort study..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 24(2024), 1 vom: 03. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Peng [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Azvudine |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12879-023-08828-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054248736 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054248736 | ||
| 003 | DE-627 | ||
| 005 | 20240104064702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240104s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-023-08828-2 |2 doi | |
| 035 | |a (DE-627)SPR054248736 | ||
| 035 | |a (SPR)s12879-023-08828-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Su, Peng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between February 15 and March 15, 2023. The primary outcome was time to sustained clinical recovery through Day 28 and secondary outcomes included the percentage of participants who died from any cause by Day 28, the average hospitilization time and expenses, the changes in liver and kidney function and adverse events. The Kaplan–Meier method and Cox regression model was used for statistical analysis. Results There was no significant difference between azvudine and paxlovid in terms of time to sustained clinical recovery (p = 0.429) and death rates (p = 0.687). As for hospitalization time and fee, no significant differences were observed between azvudine group and paxlovid group (Hospitalization time: p = 0.633; Hospitalization fee: p = 0.820). In addition, there were no significant differences in the effects of the two drugs on liver and kidney function (p > 0.05). Conclusion Among adults who were hospitalised with SARS-CoV-2 infection, azvudine was noninferior to paxlovid in terms of time to sustained clinical recovery, death rates, hospitalization time and cost, with few safety concerns. Trial registration ChiCTR2300071309; Registered 11 May 2023. Level of evidence Level III; Retrospective cohort study. | ||
| 650 | 4 | |a Covid-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nirmatrelvir–ritonavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Paxlovid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Azvudine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sustained clinical recovery |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Yang, Cong-xian |4 aut | |
| 700 | 1 | |a Wang, Xing-guang |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d London : BioMed Central, 2001 |g 24(2024), 1 vom: 03. Jan. |w (DE-627)SPR027459152 |w (DE-600)2041550-3 |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:03 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12879-023-08828-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 03 |c 01 | ||